Emergent BioSolutions (EBS) vs Opus Genetics (IRD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
Opus Genetics (IRD) has outperformed Emergent BioSolutions (EBS) over the past year, gaining 117.2% versus a loss of 28.7%. Over five years, IRD leads with a +2.8% price change compared with -86.1% for EBS. Opus Genetics is the larger company by market cap ($366.9 million vs $362.5 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EBS | IRD |
|---|---|---|
| Share price | $7.07 | $4.41 |
| Market cap | $362.50M | $366.89M |
| 1-day change | +1.73% | +0.68% |
| YTD return | -42.80% | +119.40% |
| 1-year return | -28.73% | +117.24% |
| 5-year return | -86.05% | +2.80% |
| Forward P/E | 6.76 | — |
| EPS (TTM) | $-3.40 | $-1.27 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $14.06 | $7.07 |
| 52-week low | $4.36 | $1.70 |
| Distance from 52-week high | -49.72% | -37.62% |
| Average volume | 1.16M | 2.35M |
| Shares outstanding | 51.27M | 83.20M |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IRD has outperformed EBS by 146.0 percentage points over the past year.
EBS vs IRD FAQ
Which is bigger, Emergent BioSolutions or Opus Genetics?
Opus Genetics (IRD) is larger, with a market capitalization of $366.89M compared with $362.50M for Emergent BioSolutions (EBS).
Which stock has performed better over the past year, EBS or IRD?
IRD returned +117.24% over the past 12 months, compared with -28.73% for EBS (price return, excluding dividends). Past performance does not predict future results.
Are Emergent BioSolutions and Opus Genetics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.